（原标题：秋冬季呼吸道合胞病毒来袭，钟南山详解如何防治？） 21世纪经济报道记者 唐唯珂 广州报道 随着寒潮来袭，我国多地进入流感、呼吸道合胞病毒（RSV）等呼吸道传染病高发季，"多重病毒叠加 流行"态势给公共卫生防控带来严峻挑战。中国疾控中心监测数据显示，近期全国呼吸道传染病就诊量 持续攀升，在住院的严重急性呼吸道感染病例中，0-4岁群体的RSV阳性率已连续25周居首，是婴幼儿 重症呼吸道感染的首要诱因。 "呼吸道合胞病毒已经逐渐成为全球公共卫生的威胁，特别是带来婴幼儿、老年人的重大健康挑战。"钟 南山院士此前向包括21世纪经济报道记者强调。 RSV感染呈现南北差异显著的流行特征，最新监测数据显示，0～4岁住院病例组RSV检测阳性率明显高 于其他年龄组, 婴幼儿急性下呼吸道感染住院病例中RSV阳性率更是飙升至22%-26%。 此外相关专家还指出，非药物干预措施同样具备病毒防控的重要性，个人防护、手卫生、环境消毒等具 体防控要求，尤其针对母婴护理机构、托幼场所、商场等公共场所的高频接触表面需要消毒规范，以形 成全方位、多层次的防控网络。 医防协同体系化防控 此外钟南山院士在发言中特别强调，呼吸道病毒防控需要临 ...

Core Viewpoint - The article highlights the rising stock prices of flu vaccine concept stocks, particularly Jindike (688670.SH), due to an increase in flu activity in southern China and a warning about the respiratory syncytial virus (RSV) during the flu season [3][4]. Group 1: Flu and RSV Activity - The latest flu monitoring report indicates an increase in flu activity in southern provinces and most northern provinces during the 44th week of 2025 [3]. - RSV is also a concern, with a detection rate of 8.5% among severe acute respiratory infection cases, ranking second after rhinovirus [4][5]. - In Tianjin, RSV infections have peaked earlier this year compared to last year, with a notable increase in cases during the autumn and winter seasons [5][6]. Group 2: Infection Risks and Prevention - RSV poses a significant risk, especially for children under five, with the highest risk for those under one year old [6]. - The article emphasizes the importance of preventing severe RSV and flu infections to avoid complications such as pneumonia and meningitis [6][8]. - Recommendations for prevention include vaccination for children over six months against flu, and the use of RSV monoclonal antibodies for infants under one year [6][7]. Group 3: Public Health Recommendations - Non-pharmaceutical interventions are suggested, such as maintaining social distance, frequent handwashing, wearing masks, and improving ventilation [7]. - Adults are encouraged to adopt good hygiene practices to protect children from respiratory infections during the high-risk autumn and winter seasons [7][8].

Core Insights - Respiratory Syncytial Virus (RSV) is a common respiratory virus and a leading cause of acute lower respiratory infections in children under 5 years old [1][4] - RSV spreads primarily through respiratory droplets and close contact, with increased transmission in crowded and poorly ventilated environments, especially during winter [3] - Symptoms of RSV infection resemble other respiratory illnesses and can lead to severe conditions like bronchiolitis or pneumonia in young children [4] Group 1: Understanding RSV - RSV is a major pathogen for acute lower respiratory infections in children under 5, with most children infected by age 2 [1] - Infection does not confer permanent immunity, leading to potential recurrent infections [1] Group 2: Symptoms and Risks - Symptoms include cough, nasal congestion, fever, and can develop into severe respiratory issues, particularly in infants [4] - RSV is a leading cause of hospitalization in infants, with long-term health risks such as impaired lung function and asthma [4] Group 3: Prevention Measures - Preventive measures include breastfeeding for at least 6 months, improving ventilation, avoiding crowded places, hand hygiene, and maintaining good sanitation practices [4][6] Group 4: Monoclonal Antibody Treatment - Currently, there is no vaccine for RSV in infants, but a monoclonal antibody has been approved in China to provide passive immunity [6] - The antibody works by binding to the RSV surface protein, preventing the virus from entering human cells [6] Group 5: Administration Guidelines - WHO recommends administering the RSV monoclonal antibody to infants born during the RSV season immediately after birth or at the start of the RSV season for those born before [7] Group 6: Appointment Information - In Beijing, RSV monoclonal antibody appointments can be made through specific health service applications [9][11] - A prescription from a pediatrician is required for the administration of the RSV monoclonal antibody [13]